DISCOVER A NEW WAY TO HELP
If you are a healthy male aged between 18 and 50, then you may be eligible to participate in a clinical trial investigating a treatment being developed for a range of different diseases known as autoimmune diseases.
Study Payments ranging from £3160 to £4290.
Plus Travel Expenses
study information
Simbec-Orion Clinical Pharmacology will soon be running a study to investigate a new drug called AX-158.
AX-158 is being developed for the treatment of a range of different diseases which can be broadly categorised as autoimmune and inflammatory diseases. AX-158 is specifically being developed to treat autoimmune and inflammatory diseases such as psoriasis, multiple sclerosis (MS), rheumatoid arthritis and Crohn’s disease.
Currently, there are treatment options available for these conditions; however, these treatments tend to act by blocking the activity of the whole immune system (immunosuppressants) which can leave individuals open to developing infections easily and therefore, there is an unmet need to develop potential new treatments which could be more effective.
The main objectives of this study are as follows:
- To determine the safety and tolerability of AX-158 when it is administered as single and multiple doses at different dose strengths over a period of up to 10 days.
- To investigate the concentration of AX-158 in the blood and urine, how this changes over a period of time and to evaluate whether there are differences in the concentration between different dose strengths over time and between single or multiple doses.
- To investigate the effect of food on the concentration of AX-158 in the blood following administration of AX-158 in both a fasted state (without food) and fed state (following a high-fat breakfast).
This study will be split into 3 separate parts: Part A, B & C. Part A is fully recruited. WE ARE NOW RECRUITINGFOR PART B
PPART B
The purpose of Part B is to investigate the effect of food on the safety, tolerability and concentration of AX-158 in the blood by taking a single dose of AX-158 following 2 treatment periods; one after an overnight fast and another following a high fat breakfast. Part B will consist of 1 group of 8 participants who will investigate food effect using a dose strength of AX-158 which has already been evaluated in Part A of the study.
If you participate in this part of the study, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 5 days (4 overnight stays) per treatment period with a minimum of 7-days gap between the dose of AX-158 in each of the two treatment periods. A follow-up visit will be conducted approximately 7 days after the dose of study drug in treatment period 2 and you should therefore ensure that you are able to commit to completing all visits before agreeing to participate in the study.
study timeline
Part B
If you complete this part of the study, you will receive a maximum inconvenience payment of £3160.
We also pay additional travel expenses for every visit.
APPLY NOW
Thank you for your time to register your interest in this trial please complete the below form.
OR to speak to a member of the Enrolment Team for more information or regarding any questions or queries please ring 0800 691995 and please select option 1. Alternatively drop us an email: enrolmentservices@simbecorion.com